Monopar Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Monopar Therapeutics Inc. (MNPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $300.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2021-05-13
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2021-03-31 was $300.00K, a 50.00% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-09-30 was $300.00K, a 50.00% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-06-30 was $600.00K, a 20.00% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-03-31 was $200.00K, a 60.00% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month as first filed |
|---|---|---|---|---|---|---|
| 2021-03-31 | $300.00K 10-Q · filed 2021-05-13 | |||||
| 2020-09-30 | $300.00K 10-Q · filed 2020-11-12 | $900.00K derived: sum of 2 quarters · filed 2020-11-12 | $900.00K 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $600.00K 10-Q · filed 2020-08-06 | $600.00K 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-13 | |||||
| 2019-09-30 | $200.00K 10-Q · filed 2020-11-12 | $700.00K derived: sum of 2 quarters · filed 2020-11-12 | $600.00K 10-Q · filed 2020-11-12 | $639.37K 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $500.00K 10-Q · filed 2020-08-06 | $349.41K 10-Q · filed 2019-08-08 | $500.00K 10-Q · filed 2020-08-06 | $483.85K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $500.00K 10-Q · filed 2020-05-07 | |||||
| 2018-09-30 | $170.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $249.69K derived: sum of 2 quarters · filed 2019-11-12 | $316.26K 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $79.31K 10-Q · filed 2019-08-08 | $145.88K 10-Q · filed 2019-08-08 | ||||
| 2018-03-31 | $100.00K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |